NCT04433624

Brief Summary

Introduction: Severe postoperative pain following spine surgery is a significant cause of morbidity, extended length of facility stay, and marked opioid usage The analgesic regime for postoperative pain usually includes paracetamol,NSAIDs and opioids. The opioid epidemic as well as the opioid side effects2 (sedation,respiratory depression, constipation, delayed patient mobilization) has led perioperative physicians to find a way of decreasing the use of opioids. Increasing the use of regional anesthesia is one of the measures to this end. Ultrasound-guided erector spinae plane block (ESP) is a-- popular, interfascial regional technique that was initially described for the management of thoracic neuropathic pain . As the erector spinae fascia extends from the nuchal fascia cranially to the sacrum caudally, local anesthetic agents extend through several levels, and the block can be effective over a large area The ESP block provides effective postoperative analgesic effect for 24 hours in patients undergoing lumbar spinal surgery Magnesium sulfate (MGS) is a noncompetitive antagonist of N-methyl, D-aspartate (NMDA) receptors with an analgesic effect and is essential for release of acetylcholine from the presynaptic terminals and, similar to calcium channel blockers (CCB), can prevent the entry of calcium into the cell It is suggested that magnesium has many important roles to play in nociception

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at below P25 for not_applicable postoperative-pain

Timeline
Completed

Started Jul 2020

Shorter than P25 for not_applicable postoperative-pain

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 11, 2020

Completed
5 days until next milestone

First Posted

Study publicly available on registry

June 16, 2020

Completed
1 month until next milestone

Study Start

First participant enrolled

July 18, 2020

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 10, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 10, 2020

Completed
Last Updated

July 17, 2020

Status Verified

July 1, 2020

Enrollment Period

5 months

First QC Date

June 11, 2020

Last Update Submit

July 16, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • time to first request of analgesics in hours

    time to first request of analgesics by the pateint in hours

    change from base line for 24 hours

Study Arms (2)

Group (B)

ACTIVE COMPARATOR

will receive The bilateral ESP blocks before surgery

Other: Group (B)

Group B MG

ACTIVE COMPARATOR

will receive bilateral ESP blocks performed by each side) before surgery

Other: Group (B)

Interventions

Group (B) (n=15): will receive The bilateral ESP blocks were performed by injecting 40 mL of 0.25% bupivacaine (20 mL into each side) into the fascial plane between the deep surface of the erector spinae muscle and the transverse processes of the lumbar vertebrae

Group (B)Group B MG

Eligibility Criteria

Age20 Years - 60 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • orthopedic
  • neurological patients
  • undergoing posterior lumbar spine fusion
  • American Society of Anesthesiologists (ASA) physical status 1 or 2.

You may not qualify if:

  • Contraindications for regional blocks
  • allergic reaction to drugs.
  • Patients with a history of liver, renal, heart and vascular failure, cardiac conduction disturbance.
  • opium addiction, any drug or substance abuse and chronic treatment with opium, non-steroidal anti-inflammatory drugs and calcium channel blockers (CCB).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Banī Suwayf, Egypt, 11391

Banī Suwayf, Egypt

RECRUITING

MeSH Terms

Conditions

Pain, Postoperative

Interventions

Population Groups

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and Symptoms

Intervention Hierarchy (Ancestors)

DemographyPopulation Characteristics

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant professor Doaa Rashwan

Study Record Dates

First Submitted

June 11, 2020

First Posted

June 16, 2020

Study Start

July 18, 2020

Primary Completion

December 10, 2020

Study Completion

December 10, 2020

Last Updated

July 17, 2020

Record last verified: 2020-07

Locations